Home » Topics » BioWorld Science

BioWorld Science
RSS

CTLA4Ig and LEA29Y demonstrate clinical and biological activity in RA

Nov. 20, 2001

Major approval obtained by Pharmacia/Pfizer for new antiinflammatory/analgesic

Nov. 20, 2001

Clevudine exerts potent anti-HBV activity in early clinical trial

Nov. 20, 2001

Research and clinical programs continue to advance at Photogen

Nov. 20, 2001

Novuspharma updates R&D activities

Nov. 20, 2001

Sustained antiviral effect, good safety of Coviracil in chronic HBV seen in 48-week phase I trial

Nov. 20, 2001

AASLD news: Ceplene-containing combination therapies effective in hepatitis C

Nov. 20, 2001

Adolor highlights Q3 clinical trial progress

Nov. 20, 2001

PhotoCure reports preliminary results from phase III trial of Metvix in basal cell carcinoma

Nov. 20, 2001

Launch of Xalcom/Xalacom begins in Europe

Nov. 20, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...